Treatment and IMQ challenge
Participants were equally randomized into two groups to receive oral prednisolone (0.25 mg/kg/dose) or placebo, twice daily with a 10–12-hour interval between doses, over a period of six consecutive days. On the sixth day, the volunteers received only one dose of prednisolone or placebo in the morning. The treatments were administered under supervision at the clinical research unit to ensure treatment compliance. After two days of pre-treatment with oral prednisolone or placebo, challenge with IMQ commenced (Overview of the treated sites on the back and study schedule. 